EU-approved vaccines effective against Delta variant in bloc, says EMA

Europe's drug regulator has said the COVID-19 vaccines approved in the European Union offered protection against all coronavirus variants, including Delta, but called for active monitoring by vaccine manufacturers to stay alert.

"It seems that the four vaccines that are approved in the European Union are protective against all strains that are circulating in Europe, including the Delta variant," said Marco Cavaleri, European Medicines Agency's (EMA) head of vaccine strategy, during a news briefing.

The upbeat assessment came as the World Health Organization warned that the coronavirus variant first detected in India could fuel a new wave of cases in Europe.

The EMA's head of vaccine strategy, Marco Cavaleri, said the Amsterdam-based watchdog was "aware of concerns caused by the rapid spread of the Delta variant.

"Right now it seems that the four vaccines approved in the European Union are protecting against all the strains circulating in Europe, including the Delta variant," he said.

"Emerging data from real world evidence are showing that two doses of vaccines are protective against the Delta variant."

Lab tests also showed that antibodies from the vaccines were able to neutralise Delta "so these are very reassuring news."

Four vaccines are currently approved for use in the EU: Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson. 

But while the EU has been stepping up its vaccination programme, the WHO warned that cases are on the rise again after two months of decline.

The WHO said the reversal came as the Delta variant was overtaking the original Alpha variant that emerged in Britain "very quickly".

The EMA's Cavaleri said the regulator urged manufacturers to keep checking that their jabs were effective against all new variants of the disease including the so-called 'Delta Plus'.

"There are a number of variants that have been emerging over the last months, and we expect more to come over," Cavaleri said.

"Now there is the so-called Delta Plus variant, which is the Delta variant with an additional mutation in the spike protein, that is also important and we need to check that as well."

(With inputs from agencies)